Biggest News Aggregation in the World
📰 David Wada News

David Wada News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from David Wada. Real-time updates on events, politics, business and more.

Many melanoma patients could avoid the risk for toxicity from combination therapies, study suggests

Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.
United States David Wada Emily Henderson Alexandra Ikeguchi Garyc Doolittle Elad Sharon

SWOG S1512 trial sees high response rate to p

Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of skin cancer, saw their cancer improve after treatment with the immunotherapy drug pembrolizumab in a recent clinical trial. These results from the S1512 trial are being delivered in an oral presentation at the clinical trials plenary session of the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, on April 16th.
Saint Michael United States Michaelc Wu George Negrea Josea Plaza Katiem Campbell

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science